TY  - JOUR
AU  - Zoulim, Fabien
AU  - Lenz, Oliver
AU  - Vandenbossche, Joris J
AU  - Talloen, Willem
AU  - Verbinnen, Thierry
AU  - Moscalu, Iurie
AU  - Streinu-Cercel, Adrian
AU  - Bourgeois, Stefan
AU  - Buti, Maria
AU  - Crespo, Javier
AU  - Manuel Pascasio, Juan
AU  - Sarrazin, Christoph
AU  - Vanwolleghem, Thomas
AU  - Shukla, Umesh
AU  - Fry, John
AU  - Yogaratnam, Jeysen Z
PY  - 2020
DO  - 10.1053/j.gastro.2020.04.036
UR  - http://hdl.handle.net/10668/15451
T2  - Gastroenterology
AB  - JNJ-56136379 (JNJ-6379), a capsid assembly modulator that blocks hepatitis B virus (HBV) replication, was well tolerated and demonstrated dose-proportional pharmacokinetics in healthy participants in part 1 of its first clinical trial. In part 2, we...
LA  - en
KW  - Drug
KW  - HBeAg
KW  - HBsAg
KW  - Liver
KW  - Administration, Oral
KW  - Antiviral Agents
KW  - Capsid
KW  - DNA, Viral
KW  - Dose-Response Relationship, Drug
KW  - Double-Blind Method
KW  - Female
KW  - Hepatitis B virus
KW  - Hepatitis B, Chronic
KW  - Humans
KW  - Male
KW  - Middle Aged
KW  - Organic Chemicals
KW  - Treatment Outcome
KW  - Virus Assembly
KW  - Young Adult
TI  - JNJ-56136379, an HBV Capsid Assembly Modulator, Is Well-Tolerated and Has Antiviral Activity in a Phase 1 Study of Patients With Chronic Infection.
TY  - research article
VL  - 159
ER  -